A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.
about
Engagement of CD160 receptor by HLA-C is a triggering mechanism used by circulating natural killer (NK) cells to mediate cytotoxicity.BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activityBY55/CD160 acts as a co-receptor in TCR signal transduction of a human circulating cytotoxic effector T lymphocyte subset lacking CD28 expressionDetection of membrane-bound HLA-G translated products with a specific monoclonal antibodyCD8+CD28- T cells: certainties and uncertainties of a prevalent human T-cell subset.CD160Ig fusion protein targets a novel costimulatory pathway and prolongs allograft survival.Identification and analysis of the human CD160 promoter: implication of a potential AML-1 binding site in promoter activation.Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.CD160 is essential for NK-mediated IFN-γ productionTumor necrosis factor superfamily in innate immunity and inflammation.Increased CD160 expression on circulating natural killer cells in atherogenesis.Update on hepatitis C virus-specific immunityPositive and negative regulation of cellular immune responses in physiologic conditions and diseasesThe signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulationIdentification and characterization of a transmembrane isoform of CD160 (CD160-TM), a unique activating receptor selectively expressed upon human NK cell activation.Significant enlargement of a specific subset of CD3+CD8+ peripheral blood leukocytes mediating cytotoxic T-lymphocyte activity during human immunodeficiency virus infection.T-cell activation in the intestinal mucosa.Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partnersCD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.Differential and tumor-specific expression of CD160 in B-cell malignancies.HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapy.Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.G10.3 monoclonal antibody identifies novel functional cell surface structures expressed by normal B lymphocytes and various malignant cell lines.The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors.CD160 isoforms and regulation of CD4 and CD8 T-cell responses.Study of cord blood natural killer cell suppressor activity.CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.Associations between HVEM/LIGHT/BTLA/CD160 polymorphisms and the occurrence of antibody-mediate rejection in renal transplant recipients.Expansion of CD4 phenotype among CD160 receptor-expressing lymphocytes in murine pregnancy.Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.Comparison of the immune response during acute and chronic Staphylococcus aureus infection.
P2860
Q24544012-DA583134-1D25-4FF7-A015-61DF29738A3EQ24563723-A355D97A-E510-40F0-BB46-A042A8A9119CQ28215924-1AAAC655-CC99-4487-9560-A8171BEB3854Q33832555-BA2400E3-B681-48AA-BDD2-2C4AF2B1C770Q34546418-7943746D-5574-405B-9B2D-8F11A3FF755DQ34673098-A225D256-A43F-4001-AB0B-EE393E549940Q34993584-3C2CFAA1-29D3-49F1-A6C3-593134E78535Q35040222-7B3071B5-0D97-481F-89DF-0C9F0F6DC26FQ35161483-CF445742-7987-4060-8625-C54608088393Q35245316-4036344D-A56E-4F20-AA6F-738A689CBB0BQ35743284-21C98BF3-AA37-47C2-86B8-F8D585A1BAEBQ35839496-86EB620E-3A70-48F9-8327-B2C0C51D413CQ35883043-366987A8-4135-4D22-A59D-7A7DF8EF24CBQ36053977-66377919-42D6-4D5D-9E87-0FDD0170E37EQ36320503-E52DB85C-D318-42AE-A2A0-E848DFF25E34Q36592108-A112346D-6D8E-416A-9A4D-062232CFE536Q36732698-A46E5249-0C5E-4E4C-831F-9DCA19CA385AQ37398839-09A58F91-3E71-4143-95A0-74B1FF4C486AQ37625487-2F147E64-26CA-41FB-8EDA-FA9C53C9E41CQ37625491-77500669-26B3-4691-B243-197DDA35A3A3Q37652960-CE04BF7B-2FB5-44ED-8715-5FB4F3A98689Q38636569-7B17363B-6225-4E2C-A5D8-6F3304BB73D4Q39262779-A0C2D09C-025A-4B28-8DC1-8D93397B2B12Q40966597-92EE37CE-378A-4FC2-B0A5-654BEEF5B279Q41196219-03388337-FC91-42C1-90B5-FE010772F703Q41758430-952B8F93-2EB3-4160-9E2C-0AB80B50D2B2Q43622949-DB024E67-D7CE-4DFA-8C1B-257E1CFCB5DEQ43677072-2095A6FF-E7F1-4B40-9A73-AE38BDDC7409Q47094450-AD8FCE14-8318-4041-A8CB-6335D6D7CC51Q48331912-38714287-1A6C-4AD3-8CD5-9649E04B4713Q50791583-7F677E6E-7FB1-4E2A-894D-0905AD22DEA1Q54245850-714A68FC-AD86-40BA-A1D5-06D49454CB4F
P2860
A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
A novel 80-kD cell surface str ...... with natural killer activity.
@en
type
label
A novel 80-kD cell surface str ...... with natural killer activity.
@en
prefLabel
A novel 80-kD cell surface str ...... with natural killer activity.
@en
P2093
P2860
P356
P1476
A novel 80-kD cell surface str ...... with natural killer activity.
@en
P2093
P2860
P304
P356
10.1084/JEM.178.3.1121
P407
P577
1993-09-01T00:00:00Z